Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -94K |
| Operating Income | -19M | -12M | 0 | 0 |
| EBITDA | -20M | -12M | -8M | -11M |
| Net Income | -20M | -12M | -8M | -12M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$6.71
+19.40% today
1Y Change
+14.94%
Window
Jun 27, 2025 → Jun 18, 2026
Coverage: 245 bars · Jun 27, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Satellos Bioscience Inc. Common Stock (MSLE) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $6.71 and up 14.9% across the available one-year price window (Jun 27, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +228.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +228.2%, free cash flow 0.0% with operating margin 0.0% and ROIC -20.7%. Stock Foundry combines MSLE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MSLE
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MSLE Max Drawdown
-57.03%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MSLE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$12.2M
-45.8% YoY
Free Cash Flow
-$4.0M
+7.3% YoY
Revenue Growth
+0.0%
EPS Growth
+228.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -94K |
| Operating Income | -19M | -12M | 0 | 0 |
| EBITDA | -20M | -12M | -8M | -11M |
| Net Income | -20M | -12M | -8M | -12M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 40M | 17M | 1M | 4M |
| Total Assets | 51M | 33M | 5M | 10M |
| Total Liabilities | 4M | 3M | 2M | 2M |
| Shareholder Equity | 47M | 31M | 2M | 8M |
| Total Debt | 0 | 0 | 0 | 0 |
| Net Debt | -40M | -17M | -1M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+7.3% YoY
Capital Expenditures
6K
-157.1% YoY
Free Cash Flow
4M
+7.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.